Biodelivery Sciences International

BioDelivery Sciences is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.

The development strategy focuses on the utilization of the FDA’s 505(b)(2) approval process to potentially obtain timely and efficient approval of new formulations of previously approved therapeutics which incorporate the company's licensed drug delivery technologies.

BDSI's patented drug delivery technologies include:

the BEMA™or BioErodibleMucoAdhesive (transmucosal or applied to the inner cheek lining) drug delivery technology; and
the Bioral® nanocochleate drug delivery technology, which is designed to encapsulate active pharmaceutical ingredients and potentially make them more stable as well as enable oral delivery

Utilizing its proprietary delivery technologies, BDSI is currently developing formulations of pharmaceuticals aimed principally at treatment opportunities in the areas such as:

pain
fungal infections
insomnia

Corporate Overview